Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
A commentary in response to the recent Cochrane review of clinical trial data on different anti-amyloid treatments, that states these medicines show ‘no clinically meaningful benefit’ for people with Alzheimer’s.
On 15 April, at the ADI Conference in Lyon, France, ADI shared the Alzheimer’s Disease Atlas, a first-of-its-kind website mapping the global landscape of Alzheimer’s disease.
Silverado Senior Living is the first care home provider to receive ADI Accreditation since the launch of the accreditation programme in 2021.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.
In this blog, members of the ADI team look back at 2022 and write about their hopes and aspirations for 2023.
In this blog, the authors of 'Occupational Therapy and Dementia' discuss the importance of occupational therapy in better supporting people living with dementia, as well as raising awareness about reducing the risk of dementia.
Most people associate dementia with older adults; however, dementia can impact all age groups, including children.
A joint letter was submitted in anticipation of the 3rd session of the World Health Organization's Intergovernmental Negotiating Body on 5-7 December.